Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01044303 · ClinicalTrials.gov registry record · Phase 4
Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
A Phase 4 study of Transplant; Failure, Kidney, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01044303 is a Phase 4 study of Transplant; Failure, Kidney that has completed, run by East Carolina University. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01044303, a Phase 4 study of Transplant; Failure, Kidney, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
Conditions Studied
Interventions
- DRUG Myfortic Escalation
Study Locations (1)
North Carolina
- East Carolina University - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01044303
The ClinicalTrials.gov registry entry for NCT01044303 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplant; Failure, Kidney appearing as the primary indexed condition, and to 1 intervention - of which Myfortic Escalation is the first listed.
NCT01044303 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01044303 about?
NCT01044303 is a clinical study titled "Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)". The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
What is the current status of trial NCT01044303?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2010-01. Estimated completion is 2013-04.
What conditions does trial NCT01044303 study?
This clinical trial studies the following conditions: Transplant; Failure, Kidney.
What interventions are being tested in trial NCT01044303?
The interventions under investigation include: Myfortic Escalation (DRUG).
Who is sponsoring clinical trial NCT01044303?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01044303 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant; Failure, Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.